September 19, 2024 &³¾»å²¹²õ³ó; , compared to conventional bupivacaine, reports a study in . The journal is published in the Lippincott portfolio by .
"[U]se of liposomal bupivacaine is not associated with substantially improved postoperative pain or function or with a shorter hospital course following hip hemiarthroplasty for a femoral neck fracture," according to the clinical trial report by Mitchell K. Ng, MD, and colleagues of Maimonides Medical Center, Brooklyn, New York.
Randomized trial of liposomal bupivacaine for hip fracture surgery
Liposomal bupivacaine is a long-acting local anesthetic developed for use in relieving postoperative pain, allowing drug release over up to 72 hours. Studies have shown that liposomal bupivacaine can reduce pain after various surgical procedures, including total knee or hip arthroplasty. Few studies have assessed its use following hip fracture surgery.
The new clinical trial enrolled 50 older adults undergoing hip hemiarthroplasty for isolated intracapsular femoral neck fractures. Patients were randomly assigned to intraoperative injection of either liposomal bupivacaine or standard bupivacaine hydrochloride. In both groups, a series of injections were made around the reconstructed joint toward the end of the procedure.
Pain scores, total opioid dose, and time to ambulate were assessed in blinded fashion. Time to hospital discharge, safety, and a range of secondary outcomes were evaluated as well.
The results showed no significant difference in pain scores with liposomal bupivacaine (2.3) versus standard bupivacaine (2.7), with scores remaining comparable throughout the first 48 hours postoperatively. The two groups also required similar total opioid doses (morphine milligram equivalents) for pain relief. Liposomal bupivacaine is marketed as an alternative to reduce the need for postoperative opioids.
'Worth questioning' liposomal bupivacaine in geriatric hip fracture
In both groups, time to ambulation was about one day and time to hospital discharge was about four days. Delirium and other postoperative adverse events were comparable as well.
The new study – the first randomized controlled trial of liposomal bupivacaine for hip fracture surgery in elderly patients – showed no significant difference in pain scores and other relevant outcomes, as compared with standard intraoperative bupivacaine administration.
The researchers point out some limitations of their study, including possible variations in injection technique. Dr. Ng notes: "Our study specifically focused on hip fractures, and does not contradict the growing body of evidence that liposomal bupivacaine is indeed beneficial to reduce pain scores in context of primary total joint arthroplasty."
Citing a previous report, the authors note the high cost of liposomal bupivacaine: 11 times higher than standard bupivacaine or other postoperative pain modalities. "Given the increased costs associated with liposomal bupivacaine, it is worth questioning its use in the setting of geriatric patients with a hip fracture undergoing hemiarthroplasty," Dr. Ng and coauthors conclude.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit .
###
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. 
For more information, visit , follow us on , , and .
RSS